Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Other

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Rui Zhao

Xiquan Zhang

Fei Sun

Ling Yang

Yongxin Han

Fei Liu

Zhaozhong Ding

Yilong Zhou

Yinghu Hu

Zheng Wang

Shanchun Wang

Xinlu Li

Feng Gong

Ticong Huang

Hui Zhang

Li Zhu

Hongjiang Xu

Yong Peng

Xin Tian

Yuandong Hu

Dengming Xiao

Xijie Liu

Yanqing Yang

Zhao Yang

Xiaojin Wang

Liguang Dai

Xiaowei Duan

Xinhe Xu

Jingli Wu

Wei Wei

Huifeng Xiao

Shuhui Chen

Charles Z Ding

Lei Liu

Lihong Hu

Weidong Li

Aiming Zhang

Gang Wu

Ping Dong

Lin Liu

Zhaobing Xu

Hongmei Gu

Yanlong Liu

Yingchun Liu

Chunguang Xia

Zongbin Li

Xiongxiong He

Huihui Zhang

Wenjun Geng

Xiaopeng Guo

Guangming Sang

Shanliang Zhu

Shibo Zhang

Haishan Zang

Xingjian Zhou

Yanzai Gu

Bingjie Ren

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine

The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area &#x2265;10 m/g and a particle-size distribution of X&#x2264;50 &#x3bc;m and/or X&#x2264;500 &#x3bc;m, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.

Crystal habit of quinoline derivative and preparation method for crystalline powder thereof

The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

Method for preparing trifluridine

The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.

Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer. 

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. 

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B. 

TLR7 agonist trifluoroacetate salt and crystalline form B thereof, preparation methods and uses

The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates. 

Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof

A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like. 

Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Pyridine-substituted 2-aminopyridine protein kinase inhibitors

Growing community of inventors

Lianyungang, China

Rui Zhao